Axion Biosystems is a global life science tools business with headquarters in the US, developing, producing, and marketing BEA (Bioelectronic Assay) and live-cell imaging instruments for customers in biopharma and academia. Axion’s products enable scientists to understand cell function in real-time, enabling research and the development of new therapies across various pharmaceutical segments (e.g., cell and gene therapies).
Axion at a glance
Key developments 2022
Axion acquired M-Solv in January 2022, bringing production of consumables plates in-house with positive effects on gross margins. Axion also acquired CytoSMART in March 2022, allowing Axion to expand into the next-gen live-cell imaging market. Axion also developed two products, TrayZ and Omni 12 Pro, during 2022, which are being launched in Q1 2023, enabling new growth levers.
Life sciences tools
Carbon intensity: Tons CO₂e per EUR m revenue
Total tons CO₂ emitted
Monetized climate impact
Full time employees
Gender balance, % females
Monetized employment impact
Via Summa Compliance
✔ Code of conduct
✔ Supplier code of conduct
✔ Economic Sanctions
✔ Competition Law/Antitrust
✔ Data Protection/IT Security
Science Based Targets
Axion has committed to Science Based Targets and received target validation April 2023. The company commits to reduce scope 1 and scope 2 GHG emissions 42% by 2030 compared to 2022 as base year, and to measure and reduce its scope 3 emissions.
Board Gender Diversity
Plan to improve gender diversity towards 40% has been initiated, target to achieve this during 2023.
What are the challenges Axion addresses?
How does Axion help?
Healthcare systems need better tools to understand cell function in order to target diseases and drive patient outcomes.
Axion enables multi-dimensional, interoperable live-cell analysis to improve drug discovery and development, drive breakthroughs in cell and gene therapies, and ultimately enable superior health outcomes.
Faster, more accurate and more cost-efficient drug discovery and development for precision medicine.
What impact does Axion create?
Number of publications
Number of systems sold to Cell Gene Therapy companies
Number of experiments run
Who is impacted?
Researchers and biopharma are impacted directly through more effective tools to understand cell function. Patients are impacted indirectly through breakthroughs in treatment developments.
What are the impact considerations?
Without Axion, academia and biopharma would have less insight into cell function, slowing down the time and reducing the quality of critical drug development.
Axion’s impact depends in part on how its customers in academia and biopharma choose to use its tools. Axion can engage customers to help ensure that the research and innovation it enables translates into patient outcomes downstream.